Skip to content
10-Q

Quarterly Report

ULTRAGENYX PHARMACEUTICAL INC. RARE

0001193125-25-265126

← back to feed
Filed
Nov 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 30, 2025 96.48M sh
Shares Diluted Q3 2025 · Sep 30, 2025 99.77M sh
Shares Diluted Q3 2025 · Sep 30, 2025 98.19M sh
Shares Diluted Q3 2025 · Sep 30, 2024 95.49M sh
Shares Diluted Q3 2025 · Sep 30, 2024 88.81M sh
Capex Q3 2025 · Sep 30, 2025 $5.06M
Capex Q3 2025 · Sep 30, 2024 $6.84M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$366.17M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$334.69M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $202.51M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $173.73M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $150.62M
Stockholders Equity Q3 2025 · Sep 30, 2025 $9.16M
Stockholders Equity Q3 2025 · Jun 30, 2025 $151.29M
Stockholders Equity Q3 2025 · Dec 31, 2024 $255.3M
Stockholders Equity Q3 2025 · Sep 30, 2024 $346.83M
Stockholders Equity Q3 2025 · Jun 30, 2024 $432.42M
Stockholders Equity Q3 2025 · Dec 31, 2023 $275.41M
Current Liabilities Q3 2025 · Sep 30, 2025 $340.02M
Current Liabilities Q3 2025 · Dec 31, 2024 $344.15M
Total Liabilities Q3 2025 · Sep 30, 2025 $1.17B
Total Liabilities Q3 2025 · Dec 31, 2024 $1.24B
Current Assets Q3 2025 · Sep 30, 2025 $643.21M
Current Assets Q3 2025 · Dec 31, 2024 $817.12M
Total Assets Q3 2025 · Sep 30, 2025 $1.19B
Total Assets Q3 2025 · Dec 31, 2024 $1.5B
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.81
Eps Diluted Q3 2025 · Sep 30, 2025 −$4.55
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.40
Eps Diluted Q3 2025 · Sep 30, 2024 −$4.91
Eps Basic Q3 2025 · Sep 30, 2025 −$1.81
Eps Basic Q3 2025 · Sep 30, 2025 −$4.55
Eps Basic Q3 2025 · Sep 30, 2024 −$1.40
Eps Basic Q3 2025 · Sep 30, 2024 −$4.91
Sga Expense Q3 2025 · Sep 30, 2025 $86.62M
Sga Expense Q3 2025 · Sep 30, 2025 $261.06M
Sga Expense Q3 2025 · Sep 30, 2024 $80.35M
Sga Expense Q3 2025 · Sep 30, 2024 $239.12M
Rd Expense Q3 2025 · Sep 30, 2025 $216.21M
Rd Expense Q3 2025 · Sep 30, 2025 $546.72M
Rd Expense Q3 2025 · Sep 30, 2024 $170.11M
Rd Expense Q3 2025 · Sep 30, 2024 $510.1M
Net Income Q3 2025 · Sep 30, 2025 −$180.41M
Net Income Q3 2025 · Sep 30, 2025 −$446.44M
Net Income Q3 2025 · Sep 30, 2024 −$133.52M
Net Income Q3 2025 · Sep 30, 2024 −$435.8M
Operating Income Q3 2025 · Sep 30, 2025 −$170.89M
Operating Income Q3 2025 · Sep 30, 2025 −$421.72M
Operating Income Q3 2025 · Sep 30, 2024 −$131.99M
Operating Income Q3 2025 · Sep 30, 2024 −$413.7M
Revenue Q3 2025 · Sep 30, 2025 $159.93M
Revenue Q3 2025 · Sep 30, 2025 $465.72M
Revenue Q3 2025 · Sep 30, 2024 $139.49M
Revenue Q3 2025 · Sep 30, 2024 $395.35M